Medical Products Laboratories was cited for manufacturing failures and selling unapproved prescription skin drugs.
What happened
FDA inspected the Philadelphia drug manufacturing facility from September 29 to October 16, 2025. Investigators found non-sterile drug products with gross microbiological contamination, inadequate process validation, and inadequate investigations and stability data. The letter also cites labeling for prescription skin products and says they are unapproved new drugs because no approved applications are in effect.
What FDA found
The firm did not have adequate written procedures to prevent harmful microorganisms in non-sterile drugs and used an unvalidated treatment to try to reduce contamination.
21 CFR 211.113(a)The firm did not adequately validate its manufacturing processes and relied on a study from a different facility.
21 CFR 211.100(a)The firm did not thoroughly investigate failing microbiological results, out-of-specification stability results, or complaints, and invalidated failures without adequate justification.
21 CFR 211.192The firm's stability program did not support the labeled storage conditions and expiration dates.
21 CFR 211.166(a)The firm marketed prescription skin products as new drugs without FDA-approved applications.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
What FDA wants
FDA asks the firm to provide comprehensive independent assessments, risk assessments, investigations, validation and stability remediation plans, and to engage a qualified consultant to audit its drug manufacturing quality system. The provided letter text does not state a response deadline.
Who should pay attention
- brands that buy finished prescription skin drugs from contract manufacturers
- pharmacies and patients using sodium sulfacetamide/sulfur or hydroquinone products
- quality teams overseeing contract manufacturing and supplier quality agreements
This is a summary. Read the original letter on fda.gov.